Murshid Ayesha, Gong Jianlin, Prince Thomas, Borges Thiago J, Calderwood Stuart K
Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Center for Life Sciences, 3 Blackfan Circle, Boston, Massachusetts, United States of America.
Stress Response Center, Boston University Medical Center, Boston, Massachusetts, United States of America.
PLoS One. 2015 Apr 2;10(4):e0122529. doi: 10.1371/journal.pone.0122529. eCollection 2015.
Scavenger receptor associated with endothelial cells I (SREC-I) was shown to be expressed in immune cells and to play a role in the endocytosis of peptides and antigen presentation. As our previous studies indicated that SREC-I required intact Toll-like receptor 4 (TLR4) expression for its functions in tumor immunity, we examined potential interactions between these two receptors. We have shown here that SREC-I became associated with TLR4 on binding bacterial lipopolysaccharides (LPS) in RAW 264.7 and HEK 293 cells overexpressing these two receptors. The receptors then became internalized together in intracellular endosomes. SREC-I promoted TLR4-induced signal transduction through the NF-kB and MAP kinase pathways, leading to enhanced inflammatory cytokine release. Activation of inflammatory signaling through SREC-I/TLR4 complexes appeared to involve recruitment of the receptors into detergent-insoluble, cholesterol-rich lipid microdomains that contained the small GTPase Cdc42 and the non-receptor tyrosine kinase c-src. Under conditions of SREC-I activation by LPS, TLR4 activity required Cdc42 as well as cholesterol and actin polymerization for signaling through NF-kB and MAP kinase pathways in RAW 264.7 cells. SREC-I appeared to respond differently to another ligand, the molecular chaperone Hsp90 that, while triggering SREC-I-TLR4 binding caused only faint activation of the NF-kB pathway. Our experiments therefore indicated that SREC-I could bind LPS and might be involved in innate inflammatory immune responses to extracellular danger signals in RAW 264.7 cells or bone marrow-derived macrophages.
与内皮细胞相关的清道夫受体I(SREC-I)已被证明在免疫细胞中表达,并在肽的内吞作用和抗原呈递中发挥作用。正如我们之前的研究表明,SREC-I在肿瘤免疫中的功能需要完整的Toll样受体4(TLR4)表达,我们研究了这两种受体之间的潜在相互作用。我们在此表明,在过表达这两种受体的RAW 264.7和HEK 293细胞中,SREC-I在结合细菌脂多糖(LPS)时与TLR4相关联。然后,这些受体在细胞内的内体中一起内化。SREC-I通过NF-κB和丝裂原活化蛋白激酶(MAP激酶)途径促进TLR4诱导的信号转导,导致炎症细胞因子释放增强。通过SREC-I/TLR4复合物激活炎症信号似乎涉及将受体募集到不溶于去污剂、富含胆固醇的脂质微区中,这些微区包含小GTP酶Cdc42和非受体酪氨酸激酶c-src。在LPS激活SREC-I的条件下,RAW 264.7细胞中TLR4的活性需要Cdc42以及胆固醇和肌动蛋白聚合才能通过NF-κB和MAP激酶途径进行信号传导。SREC-I对另一种配体分子伴侣Hsp90的反应似乎不同,虽然触发SREC-I-TLR4结合,但仅引起NF-κB途径的微弱激活。因此,我们的实验表明,SREC-I可以结合LPS,并可能参与RAW 264.7细胞或骨髓来源的巨噬细胞对细胞外危险信号的先天性炎症免疫反应。